Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
3,370
Views
5
CrossRef citations to date
0
Altmetric
Oncology

Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints

Nathaniel Smitha Maple Health Group, LLC, New York, NY, USACorrespondence[email protected]
,
An-Chen Fub EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA)
,
Tim Fisherc EMD Serono Research & Development Institute, Inc, Rockland, MA, USA (an affiliate of Merck KGaA)
,
Dennis Meletichea Maple Health Group, LLC, New York, NY, USA
&
Vivek Pawarb EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA)
Pages 1-6 | Received 15 Apr 2021, Accepted 19 Nov 2021, Published online: 06 Dec 2021

References

  • Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med. 2017;15(1):134.
  • Kordecka A, Walkiewicz-Zarek E, Lapa J, et al. Selection of endpoints in clinical trials: trends in European Marketing authorization practice in oncological indications. Value Health. 2019;22(8):884–890.
  • Cawston H, Genestier V, Li N, et al. Adjustment for subsequent therapies received: the impact on outcomes of an economic model of nivolumab + ipilimumab in first line metastatic renal cell carcinoma.Barcelona, Spain: ISPOR Europe; 2018.
  • Kim H, Goodall S, Liew D. Health technology assessment challenges in oncology: 20 years of value in health. Value Health. 2019;22(5):593–600.
  • McKendrick J, Malcolm B, Sheahan K, et al. The difference between regulatory and market access decisions on treatment availability for new drugs in six common cancers across Australia, Canada, and Europe. Value in Health. 2017;20(9):A467.
  • O'Rourke B, Oortwijn W, Schuller T. Announcing the new definition of health technology assessment. Value Health. 2020;23(6):824–825.
  • Ivandic V. Requirements for benefit assessment in Germany and England – overview and comparison. Health Econ Rev. 2014;4(1):12.
  • Akehurst RL, Abadie E, Renaudin N, et al. Variation in health technology assessment and reimbursement processes in Europe. Value Health. 2017;20(1):67–76.
  • Leyens L, Brand A. Early patient access to medicines: health technology assessment bodies need to catch up with new marketing authorization methods. Public Health Genomics. 2016;19(3):187–191.
  • Sola-Morales O, Volmer T, Mantovani L. Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs. J Mark Access Health Policy. 2019;7(1):1562861.
  • Mangiapane S, Velasco Garrido M. Use of surrogate end points in HTA. GMS Health Technol Assess. 2009;5:Doc12.
  • Satherley A. Understanding Payer Sensitivities when Considering the Use of Surrogate Endpoints to Substantiate Clinical Value Propositions. [cited 2019 Nov]. Available form: https://www.evidera.com/wp-content/uploads/2017/05/Surrogate-Endpoints-Used-in-Health-Technology-Assessments.pdf
  • Droeschel D, de Paz B, Houzelot D, et al. A comparison of market access evaluations for new oncology therapies in France, Germany and the UK: an analysis using the prismaccess database. Value Health. 2014;17(7):A654.
  • Chouaid C, Borget I, Braun E, et al. French health technology assessment of antineoplastic drugs indicated in the treatment of solid tumours: perspective for future trends. Target Oncol. 2016;11(4):515–534.
  • Savina M, Gourgou S, Italiano A, et al. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review. Crit Rev Oncol Hematol. 2018;123:21–41.
  • Ciani O, Davis S, Tappenden P, et al. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care. 2014;30(3):312–324.
  • Michiels S, Saad ED, Buyse M. Progression-Free survival as a surrogate for overall survival in clinical trials of targeted therapy in advanced solid tumors. Drugs. 2017;77(7):713–719.
  • Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–1568.
  • Ciani O, Buyse M, Drummond M, et al. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health. 2017;20(3):487–495.
  • Sandman L, Liliemark J. From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugs. Semin Cancer Biol. 2017;45:58–63.
  • Eichler H-G, Pignatti F, Flamion B, et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov. 2008;7(10):818–826.
  • Pauwels K, Huys I, Casteels M, et al. Industry perspectives on market access of innovative drugs: the relevance for oncology drugs. Front Pharmacol. 2016;7(144):144.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.